CRISPR Therapeutics to Present Autoimmune Disease Data at ACR Convergence

CRISPR Therapeutics announced that it will present Phase 1 clinical data for its investigational CAR T cell therapy, zugocabtagene geleucel (zugo-cel), in autoimmune disease at the American College of Rheumatology (ACR) Convergence 2026.